[{"id":"1330d05c-ce55-45d8-aef6-64434dd03682","acronym":"IL Believe","url":"https://clinicaltrials.gov/study/NCT05081609","created_at":"2021-10-18T12:53:10.136Z","updated_at":"2025-02-25T16:45:39.607Z","phase":"Phase 1/2","brief_title":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","source_id_and_acronym":"NCT05081609 - IL Believe","lead_sponsor":"Ascendis Pharma Oncology Division A/S","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Kadcyla (ado-trastuzumab emtansine) • onvapegleukin alfa (TransCon IL-2 β/γ) • resiquimod SR (TransCon TLR7/8 Agonist)"],"overall_status":"Recruiting","enrollment":" Enrollment 345","initiation":"Initiation: 01/11/2022","start_date":" 01/11/2022","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2025-02-05"},{"id":"847c8261-9d7c-4c47-a268-27585ac7ebd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02600949","created_at":"2021-01-18T12:37:39.802Z","updated_at":"2024-07-02T16:34:26.760Z","phase":"Phase 1","brief_title":"Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer","source_id_and_acronym":"NCT02600949","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Zyclara (imiquimod) • sotigalimab (PYX-107)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 05/11/2016","start_date":" 05/11/2016","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-06-12"},{"id":"1c1948c5-7233-4ceb-9300-b6eaf01714a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00799110","created_at":"2021-01-18T03:02:02.415Z","updated_at":"2024-07-02T16:34:27.111Z","phase":"Phase 2","brief_title":"Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod","source_id_and_acronym":"NCT00799110","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zyclara (imiquimod)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 08/01/2008","start_date":" 08/01/2008","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-11"},{"id":"55f18542-ba64-4815-a6b2-b0e8baf568b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04196530","created_at":"2021-01-18T20:27:08.705Z","updated_at":"2024-07-02T16:35:08.344Z","phase":"Phase 1","brief_title":"BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab","source_id_and_acronym":"NCT04196530","lead_sponsor":"Eikon Therapeutics","biomarkers":" CTLA4 • IL2 • TNFRSF9","pipe":"","alterations":" ","tags":["CTLA4 • IL2 • TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • resiquimod sulfate (EIK1001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/21/2019","start_date":" 11/21/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-22"},{"id":"dbb9746a-5e33-42bd-bd36-aa05a815c4ff","acronym":"INTERCEPT-H3","url":"https://clinicaltrials.gov/study/NCT04808245","created_at":"2021-03-22T12:52:23.649Z","updated_at":"2024-07-02T16:35:11.107Z","phase":"Phase 1","brief_title":"A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas","source_id_and_acronym":"NCT04808245 - INTERCEPT-H3","lead_sponsor":"German Cancer Research Center","biomarkers":" IFNG","pipe":" | ","alterations":" H3.3K27M","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e H3.3K27M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zyclara (imiquimod)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/15/2023","start_date":" 02/15/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-04-05"},{"id":"6bd05be8-abd8-482e-87d1-606a3bb2124b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05838599","created_at":"2023-05-01T14:04:18.513Z","updated_at":"2024-07-02T16:35:15.440Z","phase":"Phase 1","brief_title":"Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides","source_id_and_acronym":"NCT05838599","lead_sponsor":"Northwestern University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zyclara (imiquimod)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/24/2023","start_date":" 07/24/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-03-11"},{"id":"2f64949b-56d2-4517-8a8d-e52f407e983c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03559413","created_at":"2021-01-18T17:31:11.379Z","updated_at":"2024-07-02T16:35:27.228Z","phase":"Phase 1/2","brief_title":"Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL","source_id_and_acronym":"NCT03559413","lead_sponsor":"University Children's Hospital Tuebingen","biomarkers":" CD8 • CD4","pipe":" | ","alterations":" CD8 expression • CD4 expression","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • CD4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zyclara (imiquimod)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-12-04"},{"id":"adb5349d-f198-427a-8d77-d0aa610449f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00142454","created_at":"2021-01-29T06:55:16.427Z","updated_at":"2024-07-02T16:36:02.816Z","phase":"Phase 1","brief_title":"NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)","source_id_and_acronym":"NCT00142454","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CTAG1B • CD4","pipe":"","alterations":" ","tags":["CTAG1B • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zyclara (imiquimod)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 08/24/2005","start_date":" 08/24/2005","primary_txt":" Primary completion: 04/25/2006","primary_completion_date":" 04/25/2006","study_txt":" Completion: 04/25/2006","study_completion_date":" 04/25/2006","last_update_posted":"2022-10-10"},{"id":"958b0570-f348-4122-aba8-67724c61c6ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04460456","created_at":"2021-01-18T21:26:47.512Z","updated_at":"2024-07-02T16:36:08.027Z","phase":"Phase 1","brief_title":"A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors","source_id_and_acronym":"NCT04460456","lead_sponsor":"Silverback Therapeutics","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc) • pertuzumab zuvotolimod (SBT6050)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 07/27/2020","start_date":" 07/27/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-06-30"},{"id":"6aff2aba-35a1-4846-94a9-768893c1feac","acronym":"","url":"https://clinicaltrials.gov/study/NCT05234606","created_at":"2022-02-10T13:52:58.124Z","updated_at":"2024-07-02T16:36:12.983Z","phase":"Phase 1/2","brief_title":"A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors","source_id_and_acronym":"NCT05234606","lead_sponsor":"Silverback Therapeutics","biomarkers":" HER-2 • NECTIN4","pipe":" | ","alterations":" HER-2 negative • NECTIN4 expression","tags":["HER-2 • NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • NECTIN4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SBT6290"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/31/2022","primary_completion_date":" 03/31/2022","study_txt":" Completion: 03/31/2022","study_completion_date":" 03/31/2022","last_update_posted":"2022-04-12"},{"id":"2ad2c325-cb2d-4eac-988b-e223d359b314","acronym":"","url":"https://clinicaltrials.gov/study/NCT03203005","created_at":"2021-06-30T14:53:18.228Z","updated_at":"2024-07-02T16:36:50.444Z","phase":"Phase 1/2","brief_title":"IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients","source_id_and_acronym":"NCT03203005","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CV8102 • Hepavac (IMA970A) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 09/18/2017","start_date":" 09/18/2017","primary_txt":" Primary completion: 12/20/2019","primary_completion_date":" 12/20/2019","study_txt":" Completion: 12/20/2019","study_completion_date":" 12/20/2019","last_update_posted":"2020-02-05"},{"id":"8ff4f0a2-31c3-4387-a5f5-4241f7a1484d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00821964","created_at":"2021-01-18T03:07:28.863Z","updated_at":"2024-07-02T16:37:15.145Z","phase":"Phase 2","brief_title":"Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT00821964","lead_sponsor":"University of Washington","biomarkers":" HER-2 • IFNG • TGFB1 • IGFBP2","pipe":"","alterations":" ","tags":["HER-2 • IFNG • TGFB1 • IGFBP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Zyclara (imiquimod)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 11/01/2012","primary_completion_date":" 11/01/2012","study_txt":" Completion: 11/29/2012","study_completion_date":" 11/29/2012","last_update_posted":"2018-01-02"},{"id":"83c2edde-89b3-4fb5-ad76-4531e02138a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02452307","created_at":"2021-06-30T14:52:46.190Z","updated_at":"2024-07-02T16:37:18.761Z","phase":"Phase 1/2","brief_title":"Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy","source_id_and_acronym":"NCT02452307","lead_sponsor":"University Hospital Tuebingen","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zyclara (imiquimod)"],"overall_status":"Unknown status","enrollment":" Enrollment 36","initiation":"Initiation: 04/01/2004","start_date":" 04/01/2004","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 10/01/2017","study_completion_date":" 10/01/2017","last_update_posted":"2017-08-17"},{"id":"faead548-8e06-4e36-8bf9-bc8a88ce5b58","acronym":"","url":"https://clinicaltrials.gov/study/NCT00865644","created_at":"2021-01-18T03:18:07.756Z","updated_at":"2024-07-02T16:37:26.649Z","phase":"Phase 1","brief_title":"Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1","source_id_and_acronym":"NCT00865644","lead_sponsor":"Massachusetts General Hospital","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zyclara (imiquimod)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 03/01/2009","start_date":" 03/01/2009","primary_txt":" Primary completion: 04/01/2010","primary_completion_date":" 04/01/2010","study_txt":" Completion: 12/01/2013","study_completion_date":" 12/01/2013","last_update_posted":"2017-01-10"}]